GB201017316D0 - Treatment of cancer/inhibition of metastasis - Google Patents

Treatment of cancer/inhibition of metastasis

Info

Publication number
GB201017316D0
GB201017316D0 GBGB1017316.9A GB201017316A GB201017316D0 GB 201017316 D0 GB201017316 D0 GB 201017316D0 GB 201017316 A GB201017316 A GB 201017316A GB 201017316 D0 GB201017316 D0 GB 201017316D0
Authority
GB
United Kingdom
Prior art keywords
metastasis
inhibition
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1017316.9A
Other versions
GB2484513A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Priority to GB1017316.9A priority Critical patent/GB2484513A/en
Publication of GB201017316D0 publication Critical patent/GB201017316D0/en
Publication of GB2484513A publication Critical patent/GB2484513A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
GB1017316.9A 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metasesis using ranolazine or riluzole Withdrawn GB2484513A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1017316.9A GB2484513A (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metasesis using ranolazine or riluzole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1017316.9A GB2484513A (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metasesis using ranolazine or riluzole

Publications (2)

Publication Number Publication Date
GB201017316D0 true GB201017316D0 (en) 2010-11-24
GB2484513A GB2484513A (en) 2012-04-18

Family

ID=43304533

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1017316.9A Withdrawn GB2484513A (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metasesis using ranolazine or riluzole

Country Status (1)

Country Link
GB (1) GB2484513A (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835473B2 (en) * 2004-04-16 2014-09-16 Rutgers, The State University Of New Jersey Methods and compositions for treating cancer
WO2010033581A1 (en) * 2008-09-16 2010-03-25 University Of Washington Molecular modulators of the wnt/beta-catenin pathway

Also Published As

Publication number Publication date
GB2484513A (en) 2012-04-18

Similar Documents

Publication Publication Date Title
IL276362A (en) Methods of treating cancer
HK1202253A1 (en) Combination treatment of cancer
IL218575A0 (en) Treatment of cancer
EP2542081A4 (en) Compounds for treatment of cancer
SG10201508495VA (en) Combination treatment of cancer
EP2648754A4 (en) Methods of inhibiting metastasis from cancer
IL225689A0 (en) Treatment of cancer/inhibition of metastasis
HK1189272A1 (en) Methods of treating cancer
IL217796A0 (en) Inhibition of tumor metastasis using bv8-or g-csf-antagonists
IL228430A0 (en) Treatment of cancer
EP2608671A4 (en) Compounds for treatment of cancer
EP2640390A4 (en) Methods of treating cancer
EP2934499A4 (en) Inhibition of cancer growth and metastasis
GB201012845D0 (en) Inhibition of dicer function for treatment of cancer
EP2709730A4 (en) Treatment and prognosis of cancer
GB0916686D0 (en) Treatment of cancer
GB201017316D0 (en) Treatment of cancer/inhibition of metastasis
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB0921757D0 (en) Treatment of cancer
GB201017350D0 (en) Inhibition of metastatic spread of cancer
GB201121780D0 (en) Inhibition of metastatic spread of cancer
GB201116814D0 (en) Prevention and/or treratment of cancer and/or cancer metastasis

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20130228 AND 20130306

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)